Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGQ1TV)

Drug Name
ASP1941 Drug Info
Synonyms
Ipragliflozin L-proline; 951382-34-6; UNII-M6N3GK48A4; Suglat (TN); Ipragliflozin (L-Proline); M6N3GK48A4; Ipragliflozin L-proline [JAN]; Ipragliflozin L-proline (JAN); Ipragliflozin mixture with proline; DTXSID20241771; EX-A2771; L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1); HY-14894A; AKOS027321043; L-Proline, compd. with (1S)-1,5-anhydro-1-C-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-D-glucitol (1:1); AK310367; DS-11639; AC-29892; CS-0019749; D10200
Indication
Disease Entry ICD 11 Status REF
Liver disease DB90-BD99 Phase 3 [1]
Cross-matching ID
PubChem CID
10453870
ChEBI ID
CHEBI:134724
CAS Number
CAS 761423-87-4
TTD Drug ID
DMGQ1TV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Sodium/glucose cotransporter 2 (SGLT2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dapagliflozin DM28UJG Non-insulin dependent diabetes 5A11 Approved [3]
Empagliflozin DMRF9YK Type-1 diabetes 5A10 Approved [3]
Canagliflozin DMFRM1I Non-insulin dependent diabetes 5A11 Approved [4]
PF-04971729 DM79VXT Type-2 diabetes 5A11 Approved [5]
Sotagliflozin DMMLXA9 Heart failure BD10-BD13 Approved [6]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO Type-2 diabetes 5A11 Approved [7]
Remogliflozin etabonate DMW4YK1 Type-1/2 diabetes 5A10-5A11 Phase 2 [8]
LIK-066 DM32NWD Heart failure BD10-BD13 Phase 2 [9]
AVE-2268 DMA42BV Diabetic complication 5A2Y Phase 2 [10]
YM-543 DMRZBPI Type-2 diabetes 5A11 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium/glucose cotransporter 2 (SGLT2) TTLWPVF SC5A2_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT01054092) A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients. U.S. National Institutes of Health.
2 Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
3 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
4 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
5 Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
6 LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.
11 Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Aug;38(3):168-183.